PortfoliosLab logo
Alpine Immune Sciences, Inc. (ALPN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US02083G1004

CUSIP

02083G100

IPO Date

Jun 17, 2015

Highlights

Market Cap

$4.46B

EPS (TTM)

-$0.64

Year Range

$64.65 - $65.00

Target Price

$62.00

Short %

8.27%

Short Ratio

0.96

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Alpine Immune Sciences, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

Returns By Period


ALPN

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-4.26%

1M

11.24%

6M

-5.02%

1Y

8.55%

5Y*

14.02%

10Y*

10.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of ALPN, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202439.61%32.36%12.55%62.94%0.59%240.87%
202314.29%-5.12%-3.14%-2.98%32.98%3.21%21.98%-1.52%-7.29%-10.57%51.37%22.97%159.32%
2022-38.63%-3.06%8.86%2.56%1.09%-8.49%-6.58%-5.53%-4.13%-17.92%6.26%17.04%-46.93%
20212.14%-8.94%-9.56%25.19%-19.67%-15.57%-1.78%7.58%12.20%18.56%-14.39%27.89%9.92%
2020-21.87%4.00%-7.69%2.43%25.42%162.43%18.43%-29.04%7.72%-14.68%30.13%29.10%228.12%
201973.91%5.65%1.45%-7.29%-22.33%-14.78%0.71%-1.53%-5.15%-15.66%-9.28%26.73%4.35%
2018-0.98%-20.74%-8.99%-2.75%15.42%-15.70%-7.86%-3.66%-5.80%-26.86%3.67%-23.33%-67.14%
2017-1.79%24.09%6.96%-22.60%1.77%4.78%-8.82%-0.46%32.57%-13.53%4.79%6.57%25.00%
2016-39.41%-3.41%-7.95%1.44%17.97%-7.82%1.74%36.54%27.23%-27.06%-63.41%3.23%-71.06%
20151.54%12.01%-14.32%-10.80%-38.16%3.49%-6.75%-48.12%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALPN is 53, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ALPN is 5353
Overall Rank
The Sharpe Ratio Rank of ALPN is 3838
Sharpe Ratio Rank
The Sortino Ratio Rank of ALPN is 7070
Sortino Ratio Rank
The Omega Ratio Rank of ALPN is 9090
Omega Ratio Rank
The Calmar Ratio Rank of ALPN is 3131
Calmar Ratio Rank
The Martin Ratio Rank of ALPN is 3434
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alpine Immune Sciences, Inc. (ALPN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There is not enough data available to calculate the Sharpe ratio for Alpine Immune Sciences, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Alpine Immune Sciences, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Alpine Immune Sciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alpine Immune Sciences, Inc. was 97.33%, occurring on Mar 17, 2020. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.33%Aug 24, 20151149Mar 17, 2020
-12.05%Jul 20, 201511Aug 3, 201514Aug 21, 201525
-1.43%Jul 6, 20153Jul 8, 20152Jul 10, 20155
-1.14%Jul 13, 20151Jul 13, 20151Jul 14, 20152
-1.14%Jun 18, 20151Jun 18, 20156Jun 26, 20157

Volatility

Volatility Chart

The current Alpine Immune Sciences, Inc. volatility is 0.43%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


ALPN (Alpine Immune Sciences, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alpine Immune Sciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Alpine Immune Sciences, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 31.7% positive surprise.


-0.60-0.40-0.200.000.200.400.60AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024
-0.28
-0.41
Actual
Estimate

Valuation

The Valuation section provides an overview of how Alpine Immune Sciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ALPN compared to other companies in the Biotechnology industry. ALPN currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ALPN relative to other companies in the Biotechnology industry. Currently, ALPN has a P/S ratio of 71.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ALPN in comparison with other companies in the Biotechnology industry. Currently, ALPN has a P/B value of 12.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items